Skip to content

Financial Incentives for Smoking Cessation Among Mothers

Financial Incentives for Smoking Cessation Among Disadvantaged Mothers With Young Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05740098
Enrollment
198
Registered
2023-02-22
Start date
2015-06-30
Completion date
2020-10-31
Last updated
2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking

Keywords

Cigarette Smoking, Quit Smoking, Mothers

Brief summary

Investigators will examine whether adding financial incentives and nicotine replacement dual therapy to current best practices for smoking cessation (i.e. referral to counseling using a telephone quit line) increases cessation rates in mothers and reduces second-hand smoke exposure in children. While perhaps more expensive upfront compared to best practices alone, the investigators hypothesize that this treatment approach will be a more cost-effective cessation intervention.

Detailed description

Smoking prevalence among disadvantaged mothers remains at strikingly high levels (40-60%). Disadvantaged women are more likely to begin smoking at an earlier age, be heavier smokers, be nicotine dependent, and fail in their efforts to quit smoking (Kandel et al., 2009). These women and their children also suffer higher rates of smoking-related adverse health consequences. Despite widespread knowledge of the harmful effects of secondhand smoke exposure (SHSe), estimates are that 85% of children from low-income U.S. families experience chronic exposure. Children exposed to SHS are at increased risk for numerous serious health problems, including sudden infant death syndrome, more severe asthma, lower respiratory infections, and chronic middle ear disease, and maternal smoking is a particularly significant contributor to this increased morbidity and mortality. SHSe is also a substantial economic burden on the U.S. healthcare system, being estimated to increase direct medical and life-lost costs by \> $5 billion annually. Interventions developed to reduce children's SHSe have aimed to (1) decrease parental smoking around their children, (2) increase parental smoking cessation, or (3) both. Since smoking by a child's mother is a particularly significant contributor to SHSe, interventions have typically targeted smoking mothers. Regarding efforts to decrease smoking around children, studies testing relatively low-intensity interventions (e.g., written materials, brief advice) have failed to change exposure levels, while those testing more intensive interventions have had more success decreasing children's SHSe, with at least some instances of biochemically-verified changes. Clearly, more effective smoking-cessation interventions for mothers are needed to meet the public health priority of reducing SHSe among children. The investigators recognize that maternal smoking cessation will not eliminate SHSe among children since many (\ 40%) live with more than one smoker. However, the evidence is clear that smoking mothers are the primary contributors to their children's SHSe, making them the obvious first target. The overarching goal of this project is to develop an efficacious, cost-effective incentive-based smoking cessation intervention that is combined with state-of-the-art smoking-cessation pharmacotherapy practices to optimize outcomes. Participants will be 250 mothers (10 pilot and 80 per treatment condition) recruited from our university-affiliated hospital's pediatric practice, other pediatric and family medicine practices throughout the county in which our clinic is located, local offices for Women, Infants, and Children (WIC), and other recruitment strategies (e.g., ads on Facebook). Participants will be randomly assigned to one of three treatment conditions: (1) usual care for smoking cessation and protecting children from SHSe, (2) usual care combined with incentives for objectively verified smoking abstinence, and (3) usual care combined with incentives and pharmacotherapy using innovative procedures to enhance its efficacy. The investigators believe combining pharmacotherapies with incentives could be an effective strategy for surmounting adherence problems in this population by assuring that women have regular contact with clinic staff and thereby providing staff opportunities to problem-solve obstacles that may have arisen around adherence or side effects and to regularly underscore the importance and potential benefits of using the medications as prescribed. The investigators hypothesize that each of the interventions with incentives will increase smoking abstinence compared to usual care alone, but that the largest magnitude and most cost-effective treatment effects will be achieved by combining incentives with pharmacotherapy. They also hypothesize that (a) both incentives interventions will decrease child cotinine levels significantly more than usual care alone and (b) that SHSe levels will be significantly lower among children of abstainers than smokers. Taken together, developing efficacious and cost-effective interventions to increase smoking cessation interventions among disadvantaged mothers and reducing SHSe among their children is an important U.S. public health priority. The financial incentives model is effective with other treatment-recalcitrant populations and we believe has the potential to meet this important public-health challenge. Behavioral-economic theory suggests that the efficacy of the cessation intervention is at least in part attributable to providing smaller, more immediate incentives for success that act to bridge the temporal delay to the larger naturalistic rewards of improved health outcomes for mother and child. The investigators will continue to investigate the behavioral-economic processes involved in smoking among disadvantaged women and in individual differences in treatment response. Lastly, there is rapidly growing interest in the use of incentives to promote healthy behavior change in disadvantaged populations. The proposed project and others like it will be important to assuring that the necessary scientific knowledge is available to support that effort.

Interventions

BEHAVIORALBest Practices

Five As plus referral to a quit line

BEHAVIORALFinancial Incentives

Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.

DRUGNicotine Replacement Therapy

Nicotine patches and gum/lozenge provided together for dual therapy

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
University of Vermont
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Expresses interest in quitting smoking * Express willingness to initiate NRT * Mother is ≥ 18 years of age * Self-reported smoking ≥ 10 cigarettes per day for ≥ 1 year, biochemically verified * Mother has a child \< 12 years of age * Child resides with mother full-time * Not currently using any other tobacco cessation medications (e.g. Chantix) or NRT, or willing to stop use prior to participation in the study * Lives in Chittenden County, Vermont or surrounding counties * Plans on remaining in the geographical area for the next 12 months * English-speaking * Willing to let child participate in the study

Exclusion criteria

* Failing to meet any of the above criteria * Has medical contraindications to NRT products * Meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for moderate or severe alcohol or drug dependence other than nicotine in the prior 12 months (those on opioid substitution therapy are allowed) * Current/past psychotic disorder * Being suicidal * Currently pregnant or trying to become pregnant in the next 12 months * Incarceration * Refusal to participate in study

Design outcomes

Primary

MeasureTime frameDescription
7-day Point Prevalence Smoking Abstinence LevelsCollected once per woman at approximately 12- and 24- weeks following quit date in each of the three smoking armsPoint prevalence abstinence will be defined as self-report of no smoking in the past 7 days, not even a puff, with biochemical verification via breath carbon monoxide (CO) and urine cotinine. Abstinence at the 12-week (end of treatment) and 24-week assessment will be compared between the three treatment arms.
Objective Measure of Child Secondhand Smoke Exposure (SHSe)Collected twice per child at baseline, and once at approximately 6-, 12- and 24-weeks following quit dateSHSe will be defined as the level of cotinine measured in the urine of the youngest child at baseline, 6-, 12-, and 24-weeks following the mother's quit date. SHSe outcomes will be compared between the three treatment arms and between children of abstainers versus smokers independent of treatment condition. We hypothesize being able to detect greater reductions from baseline levels in the incentives compared to Best Practices treatment conditions and among abstainers compared to smokers. We report main effects of treatment condition as geometric means (+/- SEM) collapsed across the three assessment times for each treatment condition controlling for baseline values.

Secondary

MeasureTime frameDescription
Continuous Abstinence24 weeks following quit dateContinuous abstinence will be defined as self-report of no smoking in the past 7 days at each time point, not even a puff, with biochemical verification via breath CO and urine cotinine. Continuous abstinence from quit date through 24 week assessment will be compared between the three treatment arms.
7-day Point Prevalence Abstinence at 48-week Follow-up Assessment48 weeks following quit datePoint prevalence abstinence will be defined as self-report of no smoking in the past 7 days, not even a puff, with biochemical verification via breath CO and urine cotinine. We will use this data to estimate relapse rates across treatment arms and for use in comparing SHSe levels in children of abstainers versus smokers.
Smoking AbstinenceAssessed once per woman at 6-, 12-, 24-, and 48-weeks following quit date.Biochemically-verified 7-day point-prevalence smoking abstinence.

Other

MeasureTime frameDescription
Number of Times Child Received Prescription Medications.48 weeks following quit date.Number of times child received prescription medications will be compared between the three treatment arms and between abstainers versus smokers, independent of treatment condition.
Number of Inpatient Child Visits to Healthcare Center.48 weeks following quit date.Number of inpatient child visits will be compared between the three treatment arms and between abstainers versus smokers, independent of treatment condition.
Cost-effectiveness AnalysisStudy entry through 48 weeks following quit date.Cost-effectiveness will include the cost of each intervention, measured by the Brief Drug Abuse Treatment Cost Analysis Program (Brief-DATCAP) and the economic cost of treatment (fixed costs based upon proportion of time and/or space utilized by the program). Estimated treatment costs will be combined with estimated child healthcare utilization costs to represent total costs per treatment condition. Treatment costs will be compared across the three treatment arms.
Number of Outpatient Child Visits to Healthcare Center.48 weeks following quit date.Number of outpatient child visits will be compared between the three treatment arms and between abstainers versus smokers, independent of treatment condition.

Countries

United States

Participant flow

Participants by arm

ArmCount
Best Practices
Participants will receive the Five As plus a referral to a quit line. Best Practices: Five As plus referral to a quit line
68
Best Practices and Financial Incentives
Participants will receive the Five As, a referral to a quit line, and financial incentives contingent on biochemically confirmed smoking abstinence Best Practices: Five As plus referral to a quit line Financial Incentives: Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
63
Best Practices, Financial Incentives, and NRT
Participants will receive the Five As, a referral to a quit line, financial incentives contingent on biochemically confirmed smoking abstinence, and nicotine replacement therapy (NRT) provided in the form of both nicotine patches and gum/lozenge for dual therapy. Best Practices: Five As plus referral to a quit line Financial Incentives: Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date. Nicotine Replacement Therapy: Nicotine patches and gum/lozenge provided together for dual therapy
67
Total198

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up261721

Baseline characteristics

CharacteristicBest PracticesBest Practices and Financial IncentivesBest Practices, Financial Incentives, and NRTTotal
Age, Continuous32.95 years
STANDARD_DEVIATION 5.86
31.82 years
STANDARD_DEVIATION 6.18
32.88 years
STANDARD_DEVIATION 6.5
32.56 years
STANDARD_DEVIATION 6.17
Maternal smoking status
non-smoker
0 Participants0 Participants0 Participants0 Participants
Maternal smoking status
Smoking
68 Participants63 Participants67 Participants198 Participants
Race/Ethnicity, Customized
Non-Hispanic White
60 Participants57 Participants60 Participants177 Participants
Race/Ethnicity, Customized
Other
8 Participants6 Participants7 Participants21 Participants
Region of Enrollment
United States
68 participants63 participants67 participants198 participants
Sex: Female, Male
Female
68 Participants63 Participants67 Participants198 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 680 / 630 / 67
other
Total, other adverse events
0 / 680 / 630 / 67
serious
Total, serious adverse events
0 / 681 / 630 / 67

Outcome results

Primary

7-day Point Prevalence Smoking Abstinence Levels

Point prevalence abstinence will be defined as self-report of no smoking in the past 7 days, not even a puff, with biochemical verification via breath carbon monoxide (CO) and urine cotinine. Abstinence at the 12-week (end of treatment) and 24-week assessment will be compared between the three treatment arms.

Time frame: Collected once per woman at approximately 12- and 24- weeks following quit date in each of the three smoking arms

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Best Practices7-day Point Prevalence Smoking Abstinence Levels12 weeks4 Participants
Best Practices7-day Point Prevalence Smoking Abstinence Levels24 weeks6 Participants
Best Practices and Financial Incentives7-day Point Prevalence Smoking Abstinence Levels12 weeks22 Participants
Best Practices and Financial Incentives7-day Point Prevalence Smoking Abstinence Levels24 weeks14 Participants
Best Practices, Financial Incentives, and NRT7-day Point Prevalence Smoking Abstinence Levels12 weeks18 Participants
Best Practices, Financial Incentives, and NRT7-day Point Prevalence Smoking Abstinence Levels24 weeks12 Participants
Comparison: Analysis tested for significant main effects of treatment condition on 7-day point prevalence abstinence at 12- and 24-week assessmentsp-value: <0.00195% CI: [2.278, 12.689]Mixed Models Analysis
Comparison: Analysis tested for significant main effects of treatment condition on 7-day point prevalence abstinence at 12- and 24-week assessmentsp-value: 0.00395% CI: [1.538, 8.747]Mixed Models Analysis
Comparison: Analysis tested for significant main effects of treatment condition on 7-day point prevalence abstinence at 12- and 24-week assessmentsp-value: 0.25695% CI: [0.352, 1.321]Mixed Models Analysis
Comparison: Analysis tested for significant main effect of time on 7-day point prevalence abstinence at 12- and 24-week assessmentsp-value: <0.001Mixed Models Analysis
Primary

Objective Measure of Child Secondhand Smoke Exposure (SHSe)

SHSe will be defined as the level of cotinine measured in the urine of the youngest child at baseline, 6-, 12-, and 24-weeks following the mother's quit date. SHSe outcomes will be compared between the three treatment arms and between children of abstainers versus smokers independent of treatment condition. We hypothesize being able to detect greater reductions from baseline levels in the incentives compared to Best Practices treatment conditions and among abstainers compared to smokers. We report main effects of treatment condition as geometric means (+/- SEM) collapsed across the three assessment times for each treatment condition controlling for baseline values.

Time frame: Collected twice per child at baseline, and once at approximately 6-, 12- and 24-weeks following quit date

Population: This analysis is based on only children who submitted a baseline and at least one valid urine specimen between Weeks 6-24. Note that numbers in the Overall Participant Flow pertains to mothers while those shown in this section pertain to children.

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)Dispersion
Best PracticesObjective Measure of Child Secondhand Smoke Exposure (SHSe)3.53 ng/mlStandard Error 0.96
Best Practices and Financial IncentivesObjective Measure of Child Secondhand Smoke Exposure (SHSe)3.48 ng/mlStandard Error 0.92
Best Practices, Financial Incentives, and NRTObjective Measure of Child Secondhand Smoke Exposure (SHSe)8.49 ng/mlStandard Error 2.22
Comparison: Analysis tested for significant main effect of treatment condition on Child Urine Cotininep-value: 0.287Mixed Models Analysis
Comparison: Analysis tested for significant main effect of treatment condition on Child Urine Cotininep-value: 0.108Mixed Models Analysis
Comparison: Analysis tested for significant main effect of treatment condition on Child Urine Cotininep-value: 0.007Mixed Models Analysis
Comparison: Analysis tested for significant main effect of time on Child Urine Cotininep-value: 0.878Mixed Models Analysis
Secondary

7-day Point Prevalence Abstinence at 48-week Follow-up Assessment

Point prevalence abstinence will be defined as self-report of no smoking in the past 7 days, not even a puff, with biochemical verification via breath CO and urine cotinine. We will use this data to estimate relapse rates across treatment arms and for use in comparing SHSe levels in children of abstainers versus smokers.

Time frame: 48 weeks following quit date

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Best Practices7-day Point Prevalence Abstinence at 48-week Follow-up Assessment5 Participants
Best Practices and Financial Incentives7-day Point Prevalence Abstinence at 48-week Follow-up Assessment11 Participants
Best Practices, Financial Incentives, and NRT7-day Point Prevalence Abstinence at 48-week Follow-up Assessment6 Participants
Comparison: Analysis tested for significant main effect of treatment condition on 7-day point prevalence abstinence at 48-week follow-upp-value: 0.145Chi-squared
Secondary

Continuous Abstinence

Continuous abstinence will be defined as self-report of no smoking in the past 7 days at each time point, not even a puff, with biochemical verification via breath CO and urine cotinine. Continuous abstinence from quit date through 24 week assessment will be compared between the three treatment arms.

Time frame: 24 weeks following quit date

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Best PracticesContinuous Abstinence3 Participants
Best Practices and Financial IncentivesContinuous Abstinence12 Participants
Best Practices, Financial Incentives, and NRTContinuous Abstinence10 Participants
Comparison: Analysis tested for significant main effect of treatment condition on continuous abstinence at 24 weeks following quit datep-value: 0.009Chi-squared
Comparison: Analysis tested for significant main effect of treatment condition on continuous abstinence at 24 weeks following quit datep-value: 0.038Chi-squared
Comparison: Analysis tested for significant main effect of treatment condition on continuous abstinence at 24 weeks following quit datep-value: 0.531Chi-squared
Secondary

Smoking Abstinence

Biochemically-verified 7-day point-prevalence smoking abstinence.

Time frame: Collected once per woman at baseline, 6-, 12-, 24-, and 48-weeks following quit date.

Population: Participants who completed a valid baseline Cigarette-Purchase-Task (CPT) assessment. Ten participants did not have a valid assessment making total N 188 rather than 198 participants. Analyses tested for interactions of treatment and CPT Latent Factors. If there is a significant interaction (P \< 0.05) of treatment condition and CPT Latent Factors, we report results separately by treatment condition. In the absence of significant interactions, we collapse results across treatment conditions.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Best PracticesSmoking Abstinence# abstinent 6-wks49 Participants
Best PracticesSmoking Abstinence# abstinent 12-wks44 Participants
Best PracticesSmoking Abstinence# abstinent 24-wks32 Participants
Best PracticesSmoking Abstinence# abstinent 48-wks22 Participants
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Amplitude) and abstinence at 6-weeks following quit datep-value: 0.302Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Amplitude) and abstinence at 12-weeks following quit datep-value: 0.375Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Amplitude) and abstinence at 24-weeks following quit datep-value: 0.777Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Amplitude) and abstinence at 48-weeks following quit datep-value: 0.937Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Persistence) and abstinence at 6-weeks following quit datep-value: 0.678Regression, Logistic
Comparison: The analysis tested for significant interaction between baseline price sensitivity (latent factor Persistence) and treatment condition for 6-week abstinence outcomep-value: 0.018Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Persistence) and abstinence at 12-weeks following quit datep-value: 0.674Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Persistence) and abstinence at 24-weeks following quit datep-value: 0.422Regression, Logistic
Comparison: The analysis tested for significant association between baseline price sensitivity (latent factor Persistence) and abstinence at 48-weeks following quit datep-value: 0.846Regression, Logistic
Secondary

Smoking Abstinence

Biochemically-verified 7-day point-prevalence smoking abstinence.

Time frame: Assessed once per woman at 6-, 12-, 24-, and 48-weeks following quit date.

Population: Participants who completed a valid baseline delay-discounting assessment. Six participants did not have a valid assessment making total N 192 rather than 198 participants. Analyses tested for interactions of treatment and delay discounting. If there is a significant interaction (P \< 0.05) of treatment condition and baseline delay discounting, we report results separately by treatment condition. In the absence of significant interactions, we collapse results across treatment conditions.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Best PracticesSmoking Abstinence# abstinent 6-wks49 Participants
Best PracticesSmoking Abstinence# abstinent 12-wks44 Participants
Best PracticesSmoking Abstinence# abstinent 24-wks32 Participants
Best PracticesSmoking Abstinence# abstinent 48-wks22 Participants
Comparison: Analysis tested for significant main effect of baseline temporal discounting on point-prevalence abstinence at 6-weeks following quit date adjusting for treatment condition.p-value: 0.228Regression, Logistic
Comparison: Analysis tested for significant main effect of baseline temporal discounting on point-prevalence abstinence at 12-weeks following quit date adjusting for treatment condition.p-value: 0.1Regression, Logistic
Comparison: Analysis tested for significant main effect of baseline temporal discounting on point-prevalence abstinence at 24-weeks following quit date adjusting for treatment condition.p-value: 0.074Regression, Logistic
Comparison: Analysis tested for significant main effect of baseline temporal discounting on point-prevalence abstinence at 48-weeks following quit date adjusting for treatment condition.p-value: 0.484Regression, Logistic
Other Pre-specified

Cost-effectiveness Analysis

Cost-effectiveness will include the cost of each intervention, measured by the Brief Drug Abuse Treatment Cost Analysis Program (Brief-DATCAP) and the economic cost of treatment (fixed costs based upon proportion of time and/or space utilized by the program). Estimated treatment costs will be combined with estimated child healthcare utilization costs to represent total costs per treatment condition. Treatment costs will be compared across the three treatment arms.

Time frame: Study entry through 48 weeks following quit date.

Population: Cost-effectiveness analysis was not conducted because data collection on necessary outcomes was not completed due to the COVID pandemic.

Other Pre-specified

Number of Inpatient Child Visits to Healthcare Center.

Number of inpatient child visits will be compared between the three treatment arms and between abstainers versus smokers, independent of treatment condition.

Time frame: 48 weeks following quit date.

Population: Data collection on this outcome was to occur following completion of data collection on treatment outcomes. The COVID pandemic prevented data collection on this outcome.

Other Pre-specified

Number of Outpatient Child Visits to Healthcare Center.

Number of outpatient child visits will be compared between the three treatment arms and between abstainers versus smokers, independent of treatment condition.

Time frame: 48 weeks following quit date.

Population: Data collection on this outcome was to occur following completion of data collection on treatment outcomes. The COVID pandemic prevented data collection on this outcome.

Other Pre-specified

Number of Times Child Received Prescription Medications.

Number of times child received prescription medications will be compared between the three treatment arms and between abstainers versus smokers, independent of treatment condition.

Time frame: 48 weeks following quit date.

Population: Data collection on this outcome was to occur following completion of data collection on treatment outcomes. The COVID pandemic prevented data collection on this outcome.

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026